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OBJECTIVE—To identify the range of glycemic levels associated with the lowest rates of
complications and mortality in older diabetic patients.
RESEARCH DESIGN AND METHODS—We conducted a retrospective cohort study
(2004–2008) of 71,092 patients with type 2 diabetes, aged $60 years, enrolled in Kaiser Per-
manente Northern California. We speciﬁed Cox proportional hazards models to evaluate the
relationships between baseline glycated hemoglobin (A1C) and subsequent outcomes (nonfatal
complications [acute metabolic, microvascular, and cardiovascular events] and mortality).
RESULTS—Thecohort(aged71.067.4years[means6SD])hadameanA1Cof7.061.2%.
TheriskofanynonfatalcomplicationrosemonotonicallyforlevelsofA1C.6.0%(e.g.,adjusted
hazard ratio 1.09 [95% CI 1.02–1.16] for A1C 6.0–6.9% and 1.86 [1.63–2.13] for A1C
$11.0%). Mortality had a U-shaped relationship with A1C. Compared with the risk with A1C
,6.0%,mortalityriskwaslowerforA1Clevelsbetween6.0and9.0%(e.g.,0.83[0.76–0.90]for
A1C 7.0–7.9%) and higher at A1C $11.0% (1.31 [1.09–1.57]). Risk of any end point (compli-
cation or death) became signiﬁcantly higher at A1C $8.0%. Patterns generally were consistent
across age-groups (60–69, 70–79, and $80 years).
CONCLUSIONS—Observed relationships between A1C and combined end points support
setting a target of A1C ,8.0% for older patients, with the caution that A1Cs ,6.0% were
associated with increased mortality risk. Additional research is needed to evaluate the low
A1C–mortality relationship, as well as protocols for individualizing diabetes care.
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P
eople aged .60 years comprise
.40% of the type 2 diabetic popu-
lationintheU.S.,yetidentifyingthe
optimalglucose controllevelforolder pa-
tients with diabetes remains a signiﬁcant
challenge. The widely accepted recom-
mendation that all patients pursue a gly-
cated hemoglobin (A1C) ,7.0% is based
largely on the results of the UK Prospec-
tiveDiabetesStudy(1),whichactivelyex-
cluded people aged .65 years (2,3).
More recent trials have generated con-
troversy regarding the effects of pursuing
very low glucose levels (A1C ,6.5%) in
older diabetic patients. In2008, the Action
to Control Cardiovascular Risk in Diabetes
(ACCORD) Trial (4), the Action in Diabe-
tes and Vascular Disease Trial (5), and the
Veterans Affairs Diabetes Trial (6) pro-
vided some of the ﬁrst data describing
the impact of pursuing very intensive glu-
cose lowering in the elderly. Two of the
trials (5,6) found that intensive glucose
lowering prevented the progression of
nephropathy; however, none of the trials
demonstrated a clear cardiovascular
beneﬁt. Further complicating this picture,
the ACCORD trial found a higher rate of
mortality in the intensive glucose-lowering
arm (4).
As with clinical trials, observational
studies in diabetes also have provided
conﬂicting insights into the potential
impacts of different levels of glycemic
control. Numerous epidemiological stud-
ies have found a continuous relationship
between A1C levels and microvascular
andcardiovascularcomplicationswithno
clear threshold (7). However,a recent ob-
servational study (8) of the relationship
between A1C levels and mortality has re-
ported an elevated risk of mortality at
both the lower and upper ends of long-
term glucose levels.
Although the pursuit of very low
glucose levels may not always be appro-
priate,failingtoaddressveryhighglucose
levels may signiﬁcantly increase the risk
of acute metabolic events, chronic com-
plications, and mortality. Medical or-
ganizations have confused matters by
recommending differentglycemictargets.
Recommended glycemic targets range
from an A1C ,6.5% from the American
Association of Clinical Endocrinologists
(9), to an A1C ,7.0% from the American
Diabetes Association, to an A1C ,8.0%
from geriatric diabetes care guidelines
for older patients with limited life expec-
tancy (10). Unfortunately, there has been
limitedevidenceforanyofthesetargetsof
glycemic control for older patients, espe-
cially for the oldest older patients. We
sought to identify the range of glycemic
levels associated with the lowest rates of
complications and mortality in a large,
contemporary, multiethnic cohort of
older diabetic patients.
RESEARCH DESIGN AND
METHODS—The Kaiser Permanente
Northern California Diabetes Registry
(also referred to here as the Registry) is a
well-characterized population, main-
tained continuously since 1993, that has
been the basis for extensive epidemiolog-
ical research (11–13). Registry eligibility
is based on multiple sources of data, in-
cluding pharmacy records, laboratory
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Glycemic control in older diabetic patientsdata, and outpatient, emergency room,
and hospitalization diagnoses of diabetes.
Data from clinical information systems
are downloaded annually. Kaiser clini-
cians are encouraged to provide diabetes
care according to internal care guidelines
that mirror national clinical practice
guidelines (general treatment goals: A1C
,7.0%; LDL cholesterol ,100 mg/dL;
and blood pressure #130/80 mmHg).
We included type 2 diabetic subjects
from the Registry who were aged $60
years at baseline (1 January 2004) and
who had continuous Kaiser membership
and pharmacy beneﬁts for at least 12
months before baseline. From the initial
eligible population of 228,740 patients,
we excluded 62,347 for noncontinuous
Kaisermembershiporpharmacybeneﬁts,
22,427 for type 1 diabetes or unknown
diabetes (14), and 63,790 for being aged
,60 years. We additionally excluded in-
dividualswithevidenceofend-stagerenal
diseasebefore baseline (n=1,127)andno
A1C test result during the year prior to
baseline (n = 7,957). The remaining
71,092 subjects were used for these
analyses.
Time frame for analysis
Person-time follow-up started on 1 Janu-
ary 2004 and ended with the ﬁrst occur-
rence of any of the deﬁned nonfatal end
points, death, discontinuation of Kaiser
membership or pharmacy beneﬁts (dis-
continuation deﬁned as a gap of at least
3 months in coverage), or the end of our
4-year observation window (31 December
2007).
Outcomes
Nonfatal outcomes and the date of ﬁrst
occurrence were identiﬁed via hospitali-
zation records, based on established cod-
ing algorithms using primary diagnostic
(ICD-9) or current procedural terminol-
ogy (CPT) codes (see the Supplementary
Materials) (12). Acute metabolic events
were deﬁned as hospitalizations for dia-
betes with other coma, diabetes with
hyperosmolarity, diabetes with ketoaci-
dosis,anduncontrolleddiabetes.Chronic
microvascular events were deﬁned as
end-stage renal disease, amputation, or
severe diabetic eye disease. Chronic car-
diovascular events were categorized as
coronary artery disease (myocardial in-
farction, coronary artery bypass surgery,
or angioplasty), congestive heart failure,
cerebrovascular disease (ischemic or
hemorrhagicstrokeorcarotidendarterec-
tomy), or peripheral vascular disease.
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Huang and AssociatesMortality and dates of death were cap-
tured from the California State Mortality
File and Social Security Death Records.
Wealso created twocombinedoutcomes:
“Any complication” was deﬁned as the
presence of any of the three nonfatal out-
comesdescribedabove.“Anycomplication
or death” was deﬁned by the occurrence
of any of the three nonfatal outcomes or
death.
A1C
The main exposure of interest was the
most recent A1C within 1 year prior to
baseline.NorthernCaliforniaKaisermed-
icalfacilitiessendalltheirA1Csamplesto
be analyzed by a single, regional labora-
tory. This laboratory is licensed by the
state’s Department of Health Services, in-
spected and accredited by the College of
American Pathologists, and uses the stan-
dardization of A1C implemented by the
National Glycohemoglobin Standardiza-
tion Group. We categorized A1C as ,6.0,
6.0–6.9, 7.0–7.9, 8.0–8.9, 9.0–9.9, 10.0–
10.9,and$11.0%.Forstratiﬁedanalyses,
we collapsed A1C categories $9.0% be-
cause of the small numbers of patients at
that upper distribution of A1C.
Assessment of covariates
Baseline covariates evaluated in this anal-
ysis were demographics (age, sex, and
race/ethnicity); duration of diabetes; sys-
tolic blood pressure; laboratory ﬁndings
within 1 year prior to baseline, including
estimated glomerular ﬁltration rate(GFR)
and urinary albumin excretion (micro-
albuminuria or proteinuria); BMI; preva-
lent complications and comorbidities
(history of lower-extremity amputation,
photocoagulation, hospitalization for
acute metabolic event, myocardial in-
farction, stroke, congestive heart failure,
cancer, chronic lung disease, and de-
pression); smoking; number of inpatient
admissions in the previous year; and
baseline use of glucose-lowering medi-
cations.
Statistical analysis
All analyses were performed using SAS
version9.1(SASInstitute,Cary,NC),and
associations were considered statistically
signiﬁcant at the 0.05 level. We ﬁrst
calculated crude incidence densities for
each outcome (number of events per
1,000 person-years). We then speciﬁed
Cox proportional hazards models for
each outcome, generating hazard ratios
(HRs) for baseline glycemic control (A1C
,6.0% as reference group). Bivariate
analyses were ﬁrst performed followed
by multivariate analyses, accounting for
potential confounders, including age,
sex, race/ethnicity, duration of diabetes,
systolic blood pressure, use of glucose-
lowering medications, smoking status,
glucose-monitoring adherence, GFR
(chronic kidney disease stages 1–5), mi-
croalbuminuria, and proteinuria.
To address the issue of missing data,
we used multiple imputations with our
adjusted models (15). We found no sub-
stantive differences between results from
models with complete data and models
using multiple imputations. All results
presented are from models with complete
data. To address the dynamic nature of
A1C over time, we also conducted sensi-
tivity analyses using extended Cox mod-
els (time-dependent effects).
RESULTS—The mean age of the pop-
ulation was 71.0 years; 14.6% were over
t h ea g eo f8 0y e a r s( T a b l e1 ) .T h ep o p u -
lation was ethnically diverse, with 45.9%
of subjects composed of nonwhite racial/
ethnic groups.
T h em e a nA 1 Cw a s7 . 0 % .At o t a lo f
15% of the population had an A1C
,6.0%, 60% had an A1C ,7.0%, and
6.5% had an A1C $9.0%. The most fre-
quently prescribed medications for glu-
cose control were sulfonylureas (50.6%),
followed by metformin (37.7%), and any
form of insulin (17.5%). The mean dura-
tionofdiabeteswas8.3years.AcrossA1C
categories, patients with lower baseline
A1C values tended to be older and more
likely to be non-Hispanic white. Patients
with lower A1C values also were more
likely to have a shorter duration of diabe-
tes, better cholesterol control, and lower
GFR, but less evidence of other microvas-
cular complications (e.g., microalbumin-
uria, laser photocoagulation). Patients
with lower A1C levels also were much
less likely to be treated with insulin.
The mean follow-up time was 3.1
years. Chronic cardiovascular events had
the highest incidence (47.2 per 1,000
person-years), followed by mortality
(40.4 per 1,000 person-years), chronic
microvascular events (26.7 per 1,000
person-years),andacutemetabolicevents
(1.2 per 1,000 person-years) (Table 2).
The risk of acute metabolic events,
based on point estimates, increased
steeply with each unit change in A1C
above 6.0%; this increased risk became
statistically signiﬁcant above the A1C of
7.0%. The adjusted HR for an A1C of
7.0–7.9% was 2.35 (95% CI 1.31–4.23)
and increased to 11.52 (5.166–23.47) at
an A1C $11.0% (reference: A1C ,6.0%).
Adjusted HRs were somewhat attenuated
compared with unadjusted HRs, but the
steep, monotonic pattern persisted.
Therewasasimilar,stepwiserelation-
ship between baseline A1C and chronic
microvascular events. In the unadjusted
model, the increased risk associated with
higher glucose levels was signiﬁcantly dif-
ferent than the reference (A1C ,6.0%),
starting at A1C 6.0–6.9% (HR 1.56 [95%
CI 1.41–1.72]). The A1C–microvascular
event relationship was attenuated in the
adjusted model but still suggested an in-
creased risk beginning at A1C $6.0%
(1.11 [0.99–1.25]). The risk became sig-
niﬁcantly higher than the reference for
A1C levels $7.0% (1.25 [1.11–1.41]) for
A1C 7.0–7.9%.
For chronic cardiovascular events,
A1C levels $6.0% also were associated
with a signiﬁcantly increased risk in
both unadjusted and adjusted models.
The risk increased continuously without a
clear threshold level, although the risk in-
creasewas less steep thanthat observed for
acute metabolic or chronic microvascular
events.
Unlike the nonfatal complications,
mortality had a U-shaped relationship
withbaselineA1C.Inunadjustedmodels,
the risk of mortality was signiﬁcantly
lower for A1C levels between 6.0 and
8.9% relative to A1C levels ,6.0%. After
adjustment, this general pattern of lower
risk in the midrange of A1C still was ob-
served, although the lower risk for A1C
levels between 8.0 and 8.9% was no lon-
ger statistically signiﬁcant. The mortality
riskdidnotdifferstatisticallybetweenref-
erence group (A1C ,6.0%) and A1C
$9.0% in the unadjusted model, al-
though the point estimates for A1C
$10.0% indicated a somewhat higher
risk. In adjusted models only, mortality
risk became signiﬁcantly higher once
A1C levels exceeded 10.0% (HR 1.21
[95% CI 1.01–1.45]).
When evaluating “any complication,”
we found that the risk rose steadily with
each incremental rise in baseline A1C
without a clear threshold, although the
steepness of the relationship was attenu-
ated in adjusted models. After adding
death to this combined end point (i.e.,
“any complication or death”), the risk in-
creased signiﬁcantlyatA1C$6.0% inthe
unadjusted model.However,afteradjust-
ment, the risk increase wasnot signiﬁcant
until A1C was $8.0%.
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Glycemic control in older diabetic patientsThe epidemiologic patterns observed
in the overall population were similar
across the three age-groups (60–69, 70–
79, and $80 years), with some notable
exceptions(Table3).Allthreeage-groups
had U-shaped mortality curves with the
highest risk of death among patients with
A1Clevelsattheextremes(A1C,6.0and
$9.0%). For patients aged 60–69 years,
the lowest point estimate for mortality
risk was observed with A1C levels be-
tween 7.0 and 7.9%. For patients aged
$70 years, the mortality risk was statisti-
cally lower across a broader range of A1C
categories (e.g., A1C 6.0–7.9% for the
aged $80 years group) compared with
the reference group. For the “any compli-
cation” outcome, patients aged 60–69
years had a continuous, positive relation-
ship between A1C and complications
with no clear threshold. For older pa-
tients, the increased risk (relative to the
reference) of any complications was sig-
niﬁcantly higher at the threshold of A1C
$7.0%. For the “any complication or
death” outcome, there was an increased
risk in the outcome for all age-groups
when A1C exceeded 8.0%, although for
patients aged .80 years, this was statisti-
cally signiﬁcant only for A1C $9.0%.
In analyses of effect modiﬁcation, the
relationships between A1C and mortality
or the combined outcomes were not
signiﬁcantly different for those with dif-
fering durations of diabetes (data not
shown). In a sensitivity analysis using
extended Cox models that accounted for
the time-varying nature of A1C, the over-
all forms of the relationships between
A1C and complications did not change
from the baseline analyses, although the
strengths of the associations weakened,
particularly for chronic complication
events (data not shown). For extended
Cox models of the “any complication”
outcome, A1C was signiﬁcantly associ-
ated with a higher risk of events at A1C
$8.0%, instead of A1C $6.0%, whereas
for the “any complication or death” out-
come, A1C became signiﬁcantly associ-
ated with higher risk at A1C $10%,
instead of A1C $8.0%.
CONCLUSIONS—The clinical uncer-
tainty surrounding the care of older di-
abetic patients can be lessened with more
in-depth study of this important sub-
population (16). With our large, contem-
porary, geriatric cohort, we found a
U-shaped relationship between A1C
and mortality for the overall cohort
and for each age category. This U-shaped
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Huang and Associatesrelationship was not commonly reported
in older epidemiological studies but has
been found in more recent studies. Using
datasets from the 1990s, Blaum et al. (17)
found a linear relationship between A1C
and mortality, whereas Nelson et al. (18)
found that an A1C $8.0% was signiﬁ-
cantly associated with an increased risk
of mortality. In contrast, Currie et al. (8)
recently evaluated a large U.K. general
population of diabetic patients and
found a U-shaped association, with the
risk of mortality elevated at low glucose
levels (A1C 6.1–6.6%) and at high glu-
cose levels (A1C 10.1–11.2%). Likewise,
post hoc analyses of the ACCORD trial
results have revealed a U-shaped A1C-
mortality relationship in the control arm
(19). In contrast, analyses of the intensive
arm have revealed a linear A1C-mortality
association. The ACCORD ﬁndings sug-
gest that glucose-lowering treatments
mayaltertherelationshipbetweenglucose
levels and mortality. Considering all of
these studies in total, the differences be-
tween the older and more recent studies
are likely attributed to secular changes in
glycemic control levels, greater use of
combination therapies, and the arrival of
newer therapeutic classes. In our cohort,
patients with A1C ,6.0% used less insu-
linincomparisonwithotherpatients.Sul-
fonylureas were the most frequently used
oral agents, with heavy use of tolazamide
and glyburide.
It remains to be seen whether obser-
vations of an elevated risk of mortality at
low A1C levels represent an actual effect
of glucose control or are a result of other
factors associated with low A1C levels.
Older patients with lower A1C levels may
suffer frompoornutritionalstatus,frailty,
or sarcopenia, each of which may con-
tribute to an elevated mortality risk (20).
The possibility that factors other than glu-
cosecontrolmayexplaintheA1C-mortality
relationship is reinforced by the observa-
tion of a U-shaped mortality curve in a
nondiabetic population (21). The rela-
tionship between low A1C and mortality
clearly deserves additional study, espe-
cially in the elderly.
Our ﬁndings regarding A1C and the
incidence of chronic complications are
consistent with previous literature, pri-
marily conducted in younger patients,
demonstrating a continuous relationship
between glycemic control and microvas-
cular and cardiovascular complications
(7,22). Importantly, our analyses of these
outcomes indicate that these continuous
relationships also exist among the oldest
patients, conditioned on survival. For the
overall study population, no glycemic
control threshold was evident for the
“anycomplication”outcome.Forpatients
aged .70 years, a statistically signiﬁcant
higher risk was evident above a 7.0%
threshold.
The most important results from our
study concern the distinctions between
the risk of “any complication” versus the
most inclusive outcome, “any complica-
tion or death.” Unlike the risk of “any
complication,” the risk of “any complica-
tion or death” signiﬁcantly increased
relative to the reference group after A1C
levels exceeded 8.0%. This outcome inte-
gratestheU-shapedcurve associated with
mortality and the continuous curve asso-
ciated with complications. Findings for
thisoutcomeidentifyglycemicthresholds
that minimize mortality while enhancing
quality of life through the prevention of
complications.
TherelationshipbetweenbaselineA1C
and the “any complication or mortality”
outcome differed modestly by age-group,
suggesting the impact of competing mor-
tality. Within each A1C strata above the
reference level,the HR attenuated with in-
creasing age. Thus, although the general
patternwassimilar,theslopesbecameless
steep and less statistically signiﬁcant with
advancing age. The A1C 8.0% threshold
appeared to demarcate a risk increase for
patients aged 60–79 years. For patients
aged .80 years, the point estimate for
A1C 8.0–8.9% indicated an increased
risk, but this result was not statistically
different from the reference; instead, there
was a 9.0% threshold for these oldest pa-
tients. The differences in results for those
aged $80 years versus those aged 60–79
years may be attributed to mortality be-
coming an increasingly random event
(with respect to diabetes) as age increases
(23).
This study has several limitations
worth noting. Given the limitations of
observational research and our short
follow-up time, we cannot assume that
our ﬁndings have a purely causal basis,
and, thus, relationships described in this
Table 3—Age-stratiﬁed results: adjusted analyses*
Outcome
Baseline A1C
,6.0 6.0–6.9 7.0–7.9 8.0–8.9 $9
Mortality
Age-group
60–69 1 0.92 (0.79–1.07) 0.83 (0.70–0.99) 0.91 (0.74–1.11) 1.17 (0.96–1.43)
70–79 1 0.83 (0.75–0.92) 0.85 (0.75–0.96) 0.86 (0.73–1.01) 1.11 (0.93–1.32)
$80 1 0.83 (0.74–0.93) 0.83 (0.72–0.95) 1.05 (0.86–1.27) 1.20 (0.96–1.50)
Any complication
Age-group
60–69 1 1.12 (1.00–1.25) 1.20 (1.07–1.35) 1.44 (1.26–1.64) 1.58 (1.38–1.81)
70–79 1 1.08 (0.98–1.19) 1.21 (1.09–1.35) 1.35 (1.19–1.53) 1.50 (1.30–1.73)
$80 1 1.11 (0.97–1.27) 1.18 (1.02–1.38) 1.28 (1.03–1.58) 1.43 (1.12–1.83)
Any complication or death
Age-group
60–69 1 1.04 (0.94–1.14) 1.08 (0.98–1.20) 1.28 (1.14–1.44) 1.43 (1.27–1.60)
70–79 1 0.98 (0.91–1.06) 1.07 (0.98–1.17) 1.18 (1.06–1.31) 1.36 (1.20–1.53)
$80 1 0.94 (0.86–1.04) 0.96 (0.85–1.07) 1.13 (0.96–1.33) 1.25 (1.04–1.51)
*Models adjusted for sex; race/ethnicity; duration of diabetes; systolic blood pressure; use of insulin, sulfonylurea, or thiazolidinedione; smoking status; glucose-
monitoring adherence; GFR (chronic kidney disease stages 1–5); microalbuminuria; and proteinuria.
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Glycemic control in older diabetic patientsarticle should be subjected to additional
research. Residual confounding or re-
versecausalitymightexplainanapparent
short-term increase of complications or
increased mortality. We also based our
primary conclusions on the relationship
between baseline A1C and time to event,
consistent with the approach used in
most previous studies. We ﬁnd that
when we account for the time-varying
nature of A1C, the relationship between
A1C and chronic complications actually
weakens, whereas the relationship with
acutemetaboliceventsactuallystrengthens.
These differences were anticipated,
given that a time-dependent exposure
analyzed with the extended Cox model
is more sensitive to short-term effects,
whereas a ﬁxed baseline risk factor ana-
lyzed with the standard Cox model is
moresensitivetolong-termeffects(24).In
addition, our conclusions regarding A1C
thresholds might have differed with the
use of even more granular increments of
A1C (e.g., half-point increments). Our
conclusions also might have changed if
we had greater statistical power. Numer-
ous results revealed point estimates that
indicated a positive association but with
CIs bracketing unity. Although we evalu-
ated multiple outcomes, we did not eval-
uate the risk of hypoglycemia, which is
another important clinical consideration.
Our cohort was limited to patients en-
r o l l e di na ni n t e g r a t e d ,m a n a g e d - c a r e
system, where diabetes care may differ
somewhatfromthatprovidedinotherset-
tings. Previous comparisons of diabetes
care in Kaiser with that of other managed-
care settings havefoundthat the quality of
Kaiser’s care is representative of typical
care across the U.S. This cohort had rela-
tively good glycemic control on average
but did include sufﬁcient numbers of in-
dividuals with very high A1C levels to
evaluate outcomes across the spectrum
of A1C levels.
With respect to prevention of com-
plications, our results indicate that older
people have a graded relationship be-
tween A1C and complications. On the
other hand, we observed a distinct
U-shaped relationship between A1C and
mortality. Our results suggest that A1C in
older patients should be maintained be-
low 8.0% to prevent both complications
and mortality, with the caution that
A1C levels ,6% were associated with
an increased mortality risk. Additional
research is needed to identify the mecha-
nisms that underlie the increased mor-
tality among those with very low A1C.
In addition, ongoing research on care
individualization in the elderly sug-
gests that life expectancy (2), comorbid
conditions (3), and patient preferences
(25) may be important considerations
in setting glycemic goals below 8.0%.
Although we await the ﬁndings from
this important research, the observa-
tional data presented here provide addi-
tional guidance forcaringfor therapidly
growing population of older diabetic
patients.
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